EAST WINDSOR, N.J. — Aurobindo Pharma Limited has launched sildenafil sitrate tablets 25 mg, 50 mg, and 100 mg upon receiving final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application. Aurobindo’s sildenafil citrate tablets are an AB-rated generic equivalent to the reference listed drug Viagra.

The new sildenafil citrate tablets are indicated for the treatment of erectile dysfunction. The product has an estimated market size of $1.4B for the twelve months ending April 2018 according to IMS.

Sildenafil citrate tablets 25 mg, 50 mg, and 100 mg represent the latest addition to Aurobindo’s broad line of vertically integrated generic pharmaceuticals. Aurobindo’s product portfolio consists of 318 final approvals, including 35 tentative approvals, and 17 approved products from Aurolife. There are 105 additional products on file with U.S. FDA.